PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises, Inc. (NYSE: NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits,†said. ...

Heading into an important year, there is a case on paper for Nu Skin Enterprises ( NUS ) stock. Shares are cheap, trading in the range of 3x adjusted EBITDA for 2026. Guidance for this year does seem to have disappointed, sending shares lower, but marginsI've been contributing to Seeking Alpha and other investment websites since 2011, with a general (though far from rigid) focus on value over growth. I got my Series 7 and 63 back in 1999, and watched the dot-com bubble peak and then burst in real time at a ...

Core Viewpoint - Nu Skin (NUS) is identified as a potential turnaround stock, but its recovery may not be fully realized by 2026 due to a shrinking market for its skincare products, typical of multi-level marketing (MLM) companies [1]. Company Summary - Nu Skin operates in the skincare product sector and is categorized as a multi-level marketing company, which has been experiencing a decline in market size [1]. - The company's current trading position reflects the challenges faced within the MLM industry, indicating a need for strategic changes to achieve a successful turnaround [1].

Group 1 - The U.S. small-cap equities experienced modest gains in Q4 2025, supported by attractive valuations, earnings recovery, and a shift from mega-cap stocks [1] - The Aristotle Small Cap Equity Fund (Class I-2) returned 1.96% in Q4 2025, underperforming the Russell 2000 Index which had a total return of 2.19% [1] - Security selection positively impacted overall performance, while allocation effects had a negative impact [1] Group 2 - Nu Skin Enterprises, Inc. (NYSE:NUS) is a wellness and beauty care company with a market capitalization of $407.55 million [2] - The stock of Nu Skin Enterprises, Inc. closed at $8.36 per share on February 13, 2026, with a one-month return of -27.56% and a twelve-month increase of 10.58% [2] - The position in Nu Skin Enterprises, Inc. was liquidated due to deteriorating fundamental performance and an uncertain outlook amid a strategic transformation [3] Group 3 - Nu Skin Enterprises, Inc. is not among the 30 most popular stocks among hedge funds, with 20 hedge fund portfolios holding the stock at the end of Q3, unchanged from the previous quarter [3] - The company is acknowledged for its potential, but certain AI stocks are considered to offer greater upside potential with less downside risk [3]

Core Insights - Nu Skin Enterprises, Inc. (NUS) reported fourth-quarter 2025 results that fell short of Zacks Consensus Estimates, with both earnings and net sales declining year over year [1][10]. Financial Performance - Adjusted earnings for the fourth quarter were 29 cents per share, down from 38 cents per share in the same quarter last year, missing the consensus estimate of 30 cents [1][10]. - Quarterly revenues totaled $370.3 million, a decline of 16.9% year over year, with a negative impact of 0.2% from foreign currency fluctuations. On a constant-currency basis, revenues fell 16.7% [2][10]. - Adjusted gross profit was $262 million, down 17.6% from $317.9 million in the prior year, with an adjusted gross margin of 70.7%, a decrease of 70 basis points from the previous year [3][5]. - Selling expenses decreased by 20.6% to $131.3 million, representing 35.5% of revenues, down 160 basis points from the prior year [4][5]. - General and administrative expenses were $107.4 million, down 11.2% year over year, but as a percentage of revenues, they increased to 29% [5]. Customer and Sales Metrics - Sales leaders decreased by 19% year over year to 30,045, while the customer base dropped by 10% to 748,796. Paid affiliates also fell by 11% to 129,311 [2][10]. - Region-wise revenue declines were noted across various markets, with the Americas down 9.8% and Southeast Asia/Pacific down 22.7% [6]. Future Guidance - For 2026, Nu Skin anticipates revenues between $1.35 billion and $1.50 billion, indicating a potential decline of 9% to 1% from the previous year, with EPS expected to be between 80 cents and $1.20 [11][10]. - The first quarter of 2026 is projected to see revenues between $320 million and $340 million, reflecting a decline of 7-12% [12]. Financial Health - At the end of the quarter, the company had cash and cash equivalents of $238.6 million, long-term debt of $204.2 million, and total stockholders' equity of $805.2 million [7]. - The company declared a cash dividend of 6 cents per share, payable on March 11, 2026 [8].

Core Insights - NU Skin Enterprises Inc. reported revenue of $370.3 million, adjusted net income of $14.5 million, and adjusted EPS of $0.29, which were below estimates of $380.2 million, $15.1 million, and $0.30 respectively, indicating weaker-than-expected top-line results [1] - The results were at the low end of revenue guidance and the high end of EPS guidance, with a gross margin of 77.6% for the Nu Skin business [1] - Management emphasized strategic penetration into India and other emerging markets, along with margin expansion and a one-time tax benefit, as key contributors to the EPS results for FY25 [1] Financial Performance - Revenue from Rhyz was $48.52 million, comprising $42.45 million from Manufacturing and $6.07 million from Rhyz Other [1] - Selling expenses for the core business decreased to 40.8%, reflecting disciplined spending [1] Strategic Initiatives - Management remains focused on executing strategic initiatives despite the weaker top-line results [1] - The rollout of Prism iO is advancing with a pre-launch in India underway, and a full opening expected in the second half of FY26 [7] - FY26 EPS guidance is set at a midpoint of $1.00 [7]

Core Insights - The consumer staples sector has identified oversold stocks, presenting potential investment opportunities in undervalued companies [1] - The Relative Strength Index (RSI) is a key momentum indicator used to assess stock performance, with an RSI below 30 indicating that a stock is considered oversold [1] Oversold Stocks List - Notable companies with an RSI near or below 30 include NU Skin Enterprises Inc (NYSE:NUS), Coty Inc (NYSE:COTY), and Honest Company Inc (NASDAQ:HNST) [2][3]

Core Insights - Nu Skin is positioning its Prysm iO device as a key element in its strategy to enter the "wellness revolution," focusing on non-invasive carotenoid measurement to provide insights into diet, fitness, lifestyle, and nutritional supplementation [1] - The company anticipates necessary business practice changes in 2025 and early 2026 to support long-term growth and a return to profitability by the end of 2026 [2] - 2025 is seen as a pivotal year for Nu Skin, with a focus on realigning the business post-Mavely transaction, launching the Prysm iO platform, and expanding into India [3] Financial Performance - For 2025, Nu Skin reported adjusted EPS of $1.27, up from $0.84 the previous year, with total revenue of $1.49 billion [4][17] - The fourth quarter revenue was $370 million, with adjusted EPS of $0.29, and the company ended the quarter with approximately $240 million in cash and $224 million in debt [4][18] - The company guided for 2026 revenue between $1.35 billion and $1.5 billion, with adjusted EPS expected to be between $0.80 and $1.20 [4][22] Product and Market Strategy - Prysm iO is designed to provide personalized insights and product recommendations based on skin carotenoid levels, with a goal of placing over 100,000 devices by the end of 2026 and reaching 10 million "healthy households" by 2030 [6][9] - The company is preparing for a formal market opening in India in late 2026, having started pre-market operations in November 2025, with a localized product mix and a digital-first infrastructure partnership with Infosys [5][13] - Nu Skin's operating model for India includes a modified compensation plan and focuses on building digital processes and acquiring customers ahead of the formal opening [14][15] Data and Insights - Nu Skin has accumulated nearly 400 million "intelligent wellness data points" from 21 million scans, claiming to have the largest database on carotenoid health globally [7] - The company plans to leverage AI for intelligent scoring, insights, and product recommendations based on customer data [11] Future Outlook - The rollout of Prysm iO is expected to be weighted towards the latter half of 2026, with a stronger forecast anticipated for the third and fourth quarters [12] - Management remains conservative about near-term revenue contributions from India in 2026 but emphasizes the long-term potential [16] - The company aims to improve operational efficiency and support a return to growth by the end of 2026 [26]

Financial Performance - In 2025, Nu Skin Enterprises generated total revenue of $1.5 billion, with beauty products contributing $568.1 million (38.3%) and wellness products contributing $689.1 million (46.4%) to the overall revenue[23]. - Total revenue for Nu Skin in 2025 was $1,261.6 million, a decrease of 12.7% from $1,445.5 million in 2024[61]. - The total revenue for the company across all segments in 2025 was $1,485.2 million, a decline of 14.2% from $1,732.1 million in 2024[61]. - Total customers decreased from 977,039 in 2023 to 748,796 in 2025, representing a decline of approximately 23.4%[44]. - Total paid affiliates decreased from 166,886 in 2023 to 129,311 in 2025, a decline of about 22.5%[44]. - Total sales leaders decreased from 44,059 in 2023 to 30,045 in 2025, a decline of approximately 31.8%[44]. - Revenue from the Americas region was $283.0 million in 2025, representing a 19% contribution to total revenue[61]. - Revenue from Southeast Asia/Pacific was $209.8 million in 2025, accounting for 14% of total revenue[61]. - Revenue from Mainland China decreased to $195.6 million in 2025, down from $235.2 million in 2024, representing a 13% contribution[61]. - Total revenue for Rhyz was $223.6 million in 2025, a decrease of 22% from $286.6 million in 2024[61]. - Rhyz companies, a strategic investment arm, accounted for $223.6 million (15%) of total revenue in 2025, despite selling one business that generated $69.6 million in 2024[13]. Market and Customer Trends - Approximately 26% of revenue in 2025 came from the United States, with international markets contributing the remainder; revenue was negatively impacted by 0.8% due to foreign-currency fluctuations[14]. - The Southeast Asia/Pacific region saw a significant drop in customers from 106,471 in 2023 to 74,300 in 2025, a decline of about 30.2%[44]. - The Americas region had 225,527 customers in 2025, down from 231,183 in 2023, a decrease of approximately 2.4%[44]. - The company has begun pre-market activities in India, with a full market opening anticipated in the back half of 2026[60]. - Approximately 74% of the company's sales in 2025 occurred in international markets, exposing it to foreign-currency fluctuations and inflation risks[191]. Product and Innovation - The ageLOC beauty products represented 40% of the beauty product category revenue and 15% of total revenue in 2025, while ageLOC wellness products accounted for 41% of the wellness product category revenue and 19% of total revenue[23][24]. - The company launched several innovative connected beauty devices, including ageLOC LumiSpa iO and Prysm iO, with a broader commercial rollout planned for 2026[17]. - The product launch process is designed to attract new customers and affiliates, generating significant activity and revenue during introductory offerings[59]. - The introduction of the Prysm iO wellness device is planned for rollout in 2026, but there are concerns about its acceptance among Sales Leaders and its impact on existing product lines[161]. Regulatory Environment - The company faces significant regulatory scrutiny in Mainland China, impacting its ability to conduct business effectively[67]. - Sales compensation in Mainland China is limited to a maximum of 30% of the revenue generated by independent direct sellers[68]. - The regulatory environment for direct selling in the U.S. is evolving, with potential new rules from the FTC regarding earnings claims for multi-level marketers[66]. - The FDA's implementation of the Modernization of Cosmetics Regulation Act of 2022 is expected to increase compliance burdens for cosmetic products[73]. - The FDA's Food Safety Modernization Act (FSMA) enhances the FDA's authority to enforce food safety standards and mandates compliance with prevention-based regulations[79]. - Regulatory scrutiny for dietary supplements is increasing, with potential future restrictions anticipated due to negative publicity surrounding adulterated products[86]. - The company faces significant regulatory challenges in international markets, particularly in Mainland China, where product registration can take a minimum of two years[84]. - The company must comply with strict advertising regulations, which limit the claims that can be made about wellness products in various markets[88]. - The FDA's enforcement actions can lead to substantial penalties for non-compliance with advertising and product claim regulations[94]. - The company is subject to scrutiny from the FTC regarding earnings claims, which could lead to new industry standards affecting its sales compensation plan[137]. Sales and Marketing Strategy - Nu Skin's distribution channel primarily utilizes person-to-person marketing, adapting to trends in social commerce and digital tools to empower its sales force[34][35]. - The company tracks customer growth by monitoring the number of individuals who purchased directly from the company in the previous three months, including members of the sales force[40]. - The company utilizes a flexible and targeted compensation structure to enhance focus on specific products based on geographic and demographic needs[44]. - The global sales compensation plan is considered one of the most generous in the direct selling industry, providing a competitive advantage[49]. - The company has a separate compensation model for Sales Leaders in Mainland China, which is competitive with local direct selling companies[177]. Operational Challenges - The company relies heavily on its sales force, which generated virtually all revenue, and experienced high turnover rates among Sales Leaders and Paid Affiliates[198]. - The company faces significant risks from challenges to its network marketing system, which could harm its business and profitability[131]. - The company is exposed to financial risks from international operations, including foreign-currency fluctuations and regulatory changes[130]. - The company faces increased risks related to compliance and monitoring of social media content due to the borderless nature of platforms, which could lead to violations of policies and regulations[145]. - The company may incur product liability claims that could adversely affect its financial results[130]. - The company has faced interruptions in its supply chain and logistics due to the COVID-19 pandemic, impacting sales and operations[186]. - Increased transportation channel disruptions, including port congestion and labor shortages, have led to higher shipping costs and reduced profitability[207]. - The company faces risks from disruptions in manufacturing, supply chain, and distribution operations, which could adversely affect its business and financial condition[205]. Competitive Landscape - The competitive landscape includes major direct selling companies like Amway, Natura & Co, and Herbalife, which have greater financial resources and visibility[101]. - The company emphasizes innovation, value, and premium quality to differentiate its products in a highly competitive market[100]. - The company faces intense competition from both direct selling and affiliate marketing companies, which may have greater financial resources and brand recognition[165][166]. - Changes in consumer preferences and increased competition from affiliate marketing and gig economy businesses pose significant risks to the company's financial performance[157]. Employee and Human Capital Management - Approximately 2,800 full- and part-time employees were employed worldwide as of December 31, 2025, excluding about 5,800 sales employees in Mainland China[105]. - The company has implemented employee wellness programs and provides free product benefits to promote health and well-being among employees[110]. - The company’s human capital management strategy includes hiring, engagement, development, and retention to address high competition for qualified employees[106].

Core Insights - Nu Skin Enterprises reported quarterly earnings of $0.29 per share, missing the Zacks Consensus Estimate of $0.30 per share, and down from $0.38 per share a year ago [1] - The company posted revenues of $370.32 million for the quarter, missing the Zacks Consensus Estimate by 3.24%, and down from $445.55 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was -3.33%, with the company having surpassed consensus EPS estimates only once in the last four quarters [2] - A quarter ago, the company had an earnings surprise of +13.33% when it reported earnings of $0.34 per share against an expectation of $0.30 [2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.27 on revenues of $356.8 million, and for the current fiscal year, it is $1.42 on revenues of $1.53 billion [8] - The estimate revisions trend for Nu Skin was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [7] Industry Context - The Cosmetics industry, to which Nu Skin belongs, is currently in the bottom 20% of the Zacks Industry Rank, which may negatively impact stock performance [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly affect stock performance [6][9]